

Wilmington, DE; Serimmune, Goleta, CA; UNITED KINGDOM HEALTH SECURITY AGENCY (UKHSA), Salisbury, UNITED KINGDOM; University of Connecticut, Farmington, CT; VGXI, Inc., Conroe, TX; ABSS Solutions, Inc., Upper Marlboro, MD; BiosYnth SRL, Milan, ITALY; Idevax, Wijnegem, BELGIUM; IntegerBio, Inc., Gaithersburg, MD; Phoreus Biotechnology, Inc., Olathe, KS; PrecNA, LLC, North Potomac, MD; Sepragen Corp., Union City, CA; Trellis Bioscience, Inc., Redwood City, CA; AB Validation, Inc., Quebec, CANADA; AuraVax Therapeutics, Inc., Houston, TX; CuriRx, Inc., Wilmington, MA; IMA Evaluations, LLC, dba IMA Clinical Research, Tarrytown, NY; MustardSeed PMO, West Chester, PA; Symbiosis.io, LLC, Smyrna, GA; Tornado Therapeutics, Boston, MA; Amneal Pharmaceuticals of New York, LLC, Brookhaven, NY; Blue Spark Technologies, Inc., Westlake, OH; Inhalon Biopharma, Inc., Morrisville, NC; Intelligene, Inc., Taipei, TAIWAN; Rocket Science Health US Corp., Seattle, WA; Rutgers, The State University of New Jersey, Piscataway, NJ; The Administrators of the Tulane Educational Fund, New Orleans, LA; Verisim Life, Inc., San Francisco, CA; Arcturus Therapeutics Holdings, Inc., San Diego, CA; Blu Zone Bioscience & Supply Chain Solutions, LLC, Frederick, MD; Elligo Health Research, Inc., Austin, TX; Guide Biomedical Solutions, LLC, Media, PA; Integral Molecular, Philadelphia, PA; Komo Biosciences, Inc., Newton, MA; P95, BV, Leuven, BELGIUM; Southwest Research Institute, San Antonio, TX; Statistics & Data Corp., Tempe, AZ; Stoic Bio, Inc., San Diego, CA; Valaria Technical Consultants, LLC, Westminster, MD; Vaxine Pty, Ltd., Marion, AUSTRALIA; Zeteo Biomedical, LLC, Austin, TX; Concept to Market, LLC, Monrovia, MD; DSbio Consulting, LLC, Annapolis, MD; Deimos Biosciences, San Francisco, CA; GMED North America, Inc., Rockville, MD; InvisiShield Technologies, Ltd., Emeryville, CA; MigVax, Ltd., Kiryat Shmona, ISRAEL; Polaris Alpha Advanced Systems, Inc., Fredericksburg, VA; Pop Test Oncology, LLC, Cliffside Park, NJ; Sapphiros, Boston, MA; Articulate Labs, Inc., Dallas, TX; Empatica, Inc., Cambridge, MA; LifeMine Therapeutics, Inc., Cambridge, MA; Luminous Therapeutics Corp., Columbia, MD; Nabla Bio, Inc., Cambridge, MA; Qoolabs, Inc., Carlsbad, CA; Rapid Novor, Inc., Kitchener, CANADA; Scorpius BioManufacturing, San Antonio, TX; Sunflower Therapeutics

PBC, Medford, MA; GreenRoads Diagnostics, Inc., San Diego, CA; Logical Images, dba “VisualDx”, Rochester, NY; Mirai Biosciences, Cambridge, MA; The Scripps Research Institute, La Jolla, CA; AmplifyBio, LLC, West Jefferson, OH; Andelyn Biosciences, Inc., Columbus, OH; Binary Pharmaceuticals, LLC, Hot Springs, AR; BioCina PTY, Ltd., West Torrens, AUSTRALIA; Cypress Biologics, LLC, Portland, OR; Fermeate, Inc., San Francisco, CA; HMH Hospitals Corp, dba CDI, Nutley, NJ; Meso Scale Diagnostics, LLC, Rockville, MD; Systems & Technology Research, LLC, Woburn, MA; Telesis Bio, San Diego, CA; Thermo Fisher, South San Francisco, CA; University of Massachusetts Lowell, Lowell, MA; ViQi, Inc., Santa Barbara, CA; DemeTech Corp., Miami, FL; INFEX Therapeutics, Alderley Edge, UNITED KINGDOM; Mercury Bio, Inc., Santa Fe, NM; Phageolytix, Inc., Jacksonville, FL; Phenom Pharmaceuticals, LLC, Miami Beach, FL; RIBOPRO BV, Oss, NETHERLANDS; RNhale GmbH, Munich, GERMANY; The University of Chicago Medicine, Chicago, IL; Bioblue CMC/Manufacturing Consulting, LLC, San Diego, CA; Oligo Foundry, Inc., San Diego, CA; PNUVAX, Inc., Wilmington, DE; Prosoft Software, Inc., dba Prosoft Clinical, Chesterbrook, PA; Simon Williams Pharma Consulting (SWPC), LLC, Gibbsboro, NJ; Dillico, Meylan, FRANCE; INFINIFLUIDICS, Philadelphia, PA; Primrose Bio, Inc., San Diego, CA; SIMETRI, Inc., Winter Park, FL; The Trustees of the University of Pennsylvania, Philadelphia, PA; and WCG, Princeton, NJ, have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and RRPV intends to file additional written notifications disclosing all changes in membership.

On January 5, 2024, RRPV filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on April 16, 2024 (89 FR 26928).

The last notification was filed with the Department on July 11, 2024. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on October 11, 2024 (89 FR 82631).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024–30403 Filed 12–19–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—UHD Alliance

Notice is hereby given that, on October 8, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), UHD Alliance, Inc. (“UHD Alliance”) filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, TTE Corporation, Shenzhen, PEOPLE’S REPUBLIC OF CHINA has been added as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and UHD Alliance intends to file additional written notifications disclosing all changes in membership.

On June 17, 2015, UHD Alliance filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on July 17, 2015 (80 FR 42537).

The last notification was filed with the Department on July 8, 2024. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on September 26, 2024 (89 FR 78904).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024–30412 Filed 12–19–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Subcutaneous Drug Development & Delivery Consortium, Inc.

Notice is hereby given that, on October 4, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Subcutaneous Drug Development & Delivery

Consortium, Inc. (“Subcutaneous Drug Development & Delivery Consortium, Inc.”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Janssen Research & Development, LLC, Malver, PA; Novo Nordisk, Bagsvaerd, DENMARK; and Ypsomed AG, Burgdorf, SWITZERLAND have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Subcutaneous Drug Development & Delivery Consortium, Inc. intends to file additional written notifications disclosing all changes in membership.

On October 26, 2020, Subcutaneous Drug Development & Delivery Consortium, Inc. filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on December 3, 2020 (85 FR 78148).

The last notification was filed with the Department on April 25, 2024. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on September 12, 2024 (89 FR 74288).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024–30418 Filed 12–19–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Senior Healthcare Innovation Consortium

Notice is hereby given that, on October 2, 2024 pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Senior Healthcare Innovation Consortium (SHIC) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of

antitrust plaintiffs to actual damages under specified circumstances.

Specifically, AIVOT Robotics, Inc., Seattle, WA; Living Solutions, Afton, WY; Thrive360AI, San Francisco, CA; and Tornado Therapeutics, Boston, MA, have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and SHIC intends to file additional written notifications disclosing all changes in membership.

On November 2, 2022, SHIC filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on November 23, 2022 (87 FR 71677).

The last notification was filed with the Department on July 10, 2024. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on September 26, 2024 (89 FR 78902).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024–30405 Filed 12–19–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical Technology Enterprise Consortium

Notice is hereby given that, on October 7, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Medical Technology Enterprise Consortium (“MTEC”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Specifically, Artery Studios, Inc., Toronto, CANADA; Astek Diagnostics, Inc., Halethorpe, MD; BBC Entrepreneurial Training and Consulting, LLC, Chelsea, MI; Bluestaq, LLC, Colorado Springs, CO; Carrtech Corp., Dickerson, MD; Concept Plus, LLC, Fairfax, VA; Crescel, LLC, Miami Beach, FL; Culmen International, LLC, Alexandria, VA; DeployX Services, Inc.,

McLean, VA; Digital For Mental Health, Paris, FRANCE; Emvision Medical Devices, Ltd., Macquarie Park, AUSTRALIA; Galapagos Federal Systems, LLC, Kihei, HI; GoDx, Inc., Madison, WI; Government Acquisitions, Inc., Cincinnati, OH; IntelliDyne, LLC, Vienna, VA; IRegained, Inc., Sudbury, CANADA; Northeastern University, Boston, MA; Nytrix, Inc., Athens, GA; Omnix Medical, Jerusalem, ISRAEL; Perfusio Corp., Greenville, NC; Protomdx, Ltd., London, UNITED KINGDOM; PSC Biotech Corp., Pomona, CA; Razom, Inc., New York, NY; ReliOx Corp., Jacksonville, FL; SeaStar Medical, Inc., Denver, CO; SPEAR Human Performance, Inc., Tallahassee, FL; SPOC Proteomics, Inc., Scottsdale, AZ; TechWerks, LLC, Arlington Heights, IL; The Neutrino Donut, LLC, Culver City, CA; Unify Medical, Cleveland, OH; University of South Carolina, Columbia, SC; Wearabledose, Inc., Bowie, MD; Zeteo Tech, Inc., Sykesville, MD; and ZuluCare, LLC, Bethpage, NY, have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MTEC intends to file additional written notifications disclosing all changes in membership.

On May 9, 2014, MTEC filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on June 9, 2014 (79 FR 32999).

The last notification was filed with the Department on June 28, 2024. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on September 16, 2024 (89 FR 75566).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024–30411 Filed 12–19–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Naval Surface Technology & Innovation Consortium

Notice is hereby given that, on October 10, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Naval Surface Technology & Innovation